• Regulatory NewsRegulatory News

    Majority of Open PMRs and PMCs Progressing on Schedule, FDA Report Shows

    • 16 November 2018
    The majority of the open postmarket requirements (PMRs) and commitments (PMCs) in the US Food and Drug Administration’s (FDA) database continues to progress on schedule, according to data in the latest report released Friday.
  • Regulatory NewsRegulatory News

    EMA Recommends First All-Oral Treatment for Sleeping Sickness

    • 16 November 2018
    The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday announced it has adopted a positive scientific opinion of Fexinidazole Winthrop (fexinidazole), the first oral-only medicine for the treatment of human African trypanosomiasis (HAT), commonly known as sleeping sickness.
  • Regulatory NewsRegulatory News

    Draft Brexit Agreement Moves Forward on Shaky Ground

    • 15 November 2018
    EU and UK negotiators on Wednesday advanced a draft agreement setting terms for the UK’s withdrawal from the EU in March 2019 and the two parties’ relationship during a 21-month transition period.
  • Regulatory NewsRegulatory News

    PMA Denials: Why so Few?

    • 15 November 2018
    In the pharmaceutical industry, complete response letters, or rejections, are a common occurrence. And though they aren’t frequently explained in detail publicly, the public is still usually notified that the company has received such a letter. But in the world of medical devices, failing to win approval for a high-risk device is a much more closely held secret, and companies can withdraw their applications rather than be denied approval.
  • Regulatory NewsRegulatory News

    Novartis Calls for FDA Enforcement Against Biosimilar Misinformation

    • 15 November 2018
    Building off a Pfizer citizen petition on biosimilar misinformation, Novartis is calling on FDA to set the record straight on what information can be disseminated.
  • Regulatory NewsRegulatory News

    Water Quality for Pharmaceutical Use: EMA Opens Consultation

    • 15 November 2018
    With the aim of replacing guidance from 2002 on quality of water for pharmaceutical use, the European Medicines Agency (EMA) is offering new draft guidance for industry on the pharmaceutical use of different grades of water in the manufacture of active substances and medicinal products for human and veterinary use.
  • Feature ArticlesFeature Articles

    LDT Regulation: Past, Present and Future

    • 15 November 2018
    This article summarizes the regulatory history of Laboratory Developed Tests (LDTs) and describes where we are now and where we may be heading.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Most Viewed Articles

  • Insights on Upcoming Revisions to ISO 13485

    • 22 October 2018
    Following the new outcome meeting statement posted Monday by the management committee of the International Medical Device Regulators Forum (IMDRF), Focus obtained insights into upcoming revisions to the global standard for quality management systems (QMS), ISO 13485.
  • Amneal Wins First Priority Review ANDA Approval

    • 31 October 2018
    Amneal’s abbreviated new drug application (ANDA) for Carmustine for injection was the first ANDA to win a priority review – a new designation for generic drugs thanks to the FDA Reauthorization Act of 2017 (FDARA).
  • FDA Proposes Changes to Informed Consent Rules

    • 13 November 2018
    The US Food and Drug Administration (FDA) on Tuesday proposed changes that would allow institutional review boards (IRBs) to waive or alter requirements for obtaining informed consent for certain clinical trials involving minimal risk to participants.
  • FDA Flags Violations at Medical Device Firms in Sweden, Canada, Spain, UK

    • 30 October 2018
    Device firms in Sweden, Canada, Spain and the UK separately drew four US Food and Drug Administration (FDA) warning letters over good manufacturing practice (GMP) violations.
Regulatory Focus ArticlesRSS 2.0